scholarly journals Bone Marrow Dosimetric Analysis of Lymphopenia in Patients With Esophageal Squamous Cell Carcinoma Treated With Chemoradiotherapy

2020 ◽  
Author(s):  
Qian Wang ◽  
Qingtao Qiu ◽  
Zicheng Zhang ◽  
Jing Zhang ◽  
Guanghui Yang ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Esophageal Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Peripheral Blood ◽  
Peripheral Blood Lymphocytes ◽  
Relative Volume ◽  
Vertebra Body

Abstract Background: Lymphocytes as a marker of immune function are essential to the immune response. Sternum and vertebra bone marrow (BM) exposed to radiation may affect lymphocytes during radiotherapy (RT) for esophageal carcinoma (EC). We analyzed the relationship among peripheral blood lymphocytes, exposed sternum and vertebra body BM, and overall survival (OS) to find BM dosimetric parameters of lymphopenia during chemoradiotherapy (CRT) for patients with esophageal squamous cell carcinoma (ESCC). Methods: We examined 476 ESCC patients from January 2012 to January 2015, all of whom received concurrent or sequential CRT. Absolute lymphocyte counts (ALC) during RT of each patient were collected from the routine workup at the following RT times: pretreatment ALC (ALC0), at 1–5, 6–10, 11–15, 16–20, and 21–25, and more than 26 sessions (called ALC1–6, respectively). The sternum and vertebral body BM were delineated in accordance with uniform standards, and the irradiated volumes were calculated by dose-volume histograms (DVH). The Kaplan–Meier method and Cox proportional hazards regression were used to analyze the survival of the patients. Comparisons of DVH were performed using the Mann–Whitney U test or two-sample t-test where appropriate. Results: A relative volume of sternum BM irradiated by more than 20 Gy could clearly affect the peripheral blood lymphocytes. The V20 of sternum BM and V50 of vertebra body BM were related to the OS of the patients, and the level of ALC2(at 6–10 times of RT) could predict the patients’ outcomes. The Cox regression analyses showed that the 218 patients with ALC2 ≥ 0.8×109/L had a significantly longer OS (47.0 vs. 30.9, p<0.0001) than the 258 patients with ALC2 < 0.8×109/L. Conclusion: In patients with ESCC, the relative volume of sternum BM irradiated by more than 20 Gy was associated with lymphocyte. The V20 of the sternum BM and the V50 of the vertebra body BM were related to the OS of the patients. The level of ALC2 is a significant prognostic factor in esophageal carcinoma patients.

scholarly journals Clinical significance of tumor cells in the peripheral blood of patients with esophageal squamous cell carcinoma

Medicine ◽  
2019 ◽  
Vol 98 (6) ◽  
pp. e13921 ◽  
Author(s):  
Lu Han ◽  
Yun-Jie Li ◽  
Wei-Di Zhang ◽  
Ping-Ping Song ◽  
Hao Li ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Tumor Cells ◽  
Clinical Significance ◽  
Squamous Cell ◽  
Peripheral Blood

The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma

Esophagus ◽  
2018 ◽  
Vol 15 (2) ◽  
pp. 103-108 ◽  
Author(s):  
Yasunori Akutsu ◽  
Kentaro Murakami ◽  
Masayuki Kano ◽  
Takeshi Toyozumi ◽  
Yasunori Matsumoto ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Peripheral Blood

scholarly journals Auraptene Attenuates Malignant Properties of Esophageal Stem-Like Cancer Cells

2016 ◽  
Vol 16 (4) ◽  
pp. 519-527 ◽  
Author(s):  
Saffiyeh Saboor-Maleki ◽  
Fatemeh B. Rassouli ◽  
Maryam M. Matin ◽  
Mehrdad Iranshahi
Keyword(s):  
Polymerase Chain Reaction ◽  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Esophageal Carcinoma ◽  
Cell Carcinoma ◽  
Cancer Cells ◽  
Real Time ◽  
Squamous Cell ◽  
Chain Reaction ◽  
Polymerase Chain

The high incidence of esophageal squamous cell carcinoma has been reported in selected ethnic populations including North of Iran. Low survival rate of esophageal carcinoma is partially due to the presence of stem-like cancer cells with chemotherapy resistance. In the current study, we aimed to determine the effects of auraptene, an interesting dietary coumarin with various biological activities, on malignant properties of stem-like esophageal squamous cell carcinoma, in terms of sensitivity to anticancer drugs and expression of specific markers. To do so, the half maximal inhibitory concentration values of auraptene, cisplatin, paclitaxel, and 5-fluorouracil were determined on esophageal carcinoma cells (KYSE30 cell line). After administrating combinatorial treatments, including nontoxic concentrations of auraptene + cisplatin, paclitaxel, or 5-fluorouracil, sensitivity of cells to chemical drugs and also induced apoptosis were assessed. In addition, quantitative real-time polymerase chain reaction was used to study changes in the expression of tumor suppressor proteins 53 and 21 ( P53 and P21), cluster of differentiation 44 ( CD44), and B cell-specific Moloney murine leukemia virus integration site 1 ( BMI-1) upon treatments. Results of thiazolyl blue assay revealed that auraptene significantly ( P < .05) increased toxicity of cisplatin, paclitaxel, and 5-fluorouracil in KYSE30 cells, specifically 72 hours after treatment. Conducting an apoptosis assay using flow cytometry also confirmed the synergic effects of auraptene. Results of quantitative real-time polymerase chain reaction revealed significant ( P < .05) upregulation of P53 and P21 upon combinatorial treatments and also downregulation of CD44 and BMI-1 after auraptene administration. Current study provided evidence, for the first time, that auraptene attenuates the properties of esophageal stem-like cancer cells through enhancing sensitivity to chemical agents and reducing the expression of CD44 and BMI-1 markers.

scholarly journals Expressions of HPV 16-E6 in esophageal carcinoma and it's clinical significance

2015 ◽  
Vol 6 (6) ◽  
pp. 39-42
Author(s):  
Xing Zhao ◽  
Rajina Sahi ◽  
Yu-Yang Zhao ◽  
Jun Wang ◽  
Chun- Hui Li
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Esophageal Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Immunohistochemical Method ◽  
Esophageal Mucosa ◽  
Medical Sciences ◽  
Hpv 16 ◽  
Hpv16 E6

Aim: To explore the association between HPV16-E6 protein and esophageal squamous cell carcinoma.Materials and Methods: SP immunohistochemical method was used to examine the expression of HPV 16-E6 in 50 cases of esophageal squamous cell carcinoma, 10 cases of normal esophageal squamous cell and 10 cases of adjacent tissue.Results: The expressions of HPV 16-E6 was significantly higher in esophageal carcinoma than in normal esophageal mucosa and in adjacent tissue. The expressions of HPV 16-E6 had correlation with invasive depth (P<0.05), but not with patient age, lymph node metastasis, tumor size (P>0.05).Conclusion: HPV 16-E6 can promote the growth and metastasis of esophageal squamous cell carcinoma and can be a prognostic factor of esophageal squamous cell carcinoma.  DOI: http://dx.doi.org/10.3126/ajms.v6i6.12537 Asian Journal of Medical Sciences Vol.6(6) 2015 39-42

Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e15559-e15559
Author(s):  
Xi Wang ◽  
Bo Zhang ◽  
Xuelian Chen ◽  
Hongnan Mo ◽  
Dawei Wu ◽  
...  
Keyword(s):  
Overall Survival ◽  
Squamous Cell Carcinoma ◽  
Lactate Dehydrogenase ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Disease Progression ◽  
Squamous Cell ◽  
Peripheral Blood ◽  
Group Performance ◽  
Blood Biomarkers

e15559 Background: A small proportion of patients with advanced esophageal squamous cell carcinoma (ESCC) could benefit from immune checkpoint inhibitors, and reliable peripheral blood biomarkers for outcomes of anti-PD-1 immunotherapy were not identified in ESCC. Methods: A total of 43 patients were retrospectively reviewed in the ESCC cohort of a phase I trial from our center. All patients received intravenous camrelizumab (SHR-1210), a novel anti-PD-1 antibody, at a dose of 60 mg, 200 mg or 400 mg (4-week interval after first dose followed by a 2-week schedule) and repeated every two weeks until disease progression or intolerable toxicity. The associations between lactate dehydrogenase (LDH) as well as other peripheral blood biomarkers at baseline and the efficacy of camrelizumab were also investigated. Results: With a median follow-up of 19.6 months, the overall response rate was 25.6% (11/43), including one complete response. Median progression-free survival (PFS) and overall survival were 2.0 months (95% CI: 0-4.1 months) and 8.0 months (95% CI: 7.2-8.8 months), respectively. Notably, four patients achieved a PFS exceeding 12 months, including three patients with a long-lasting duration of response over 1 year. Patients with an elevated baseline lactate dehydrogenase had lower tumor response rates (8.3% vs. 32.3%, p = 0.02) as well as shorter PFS (median: 1.8 vs. 4.0 months; HR 0.39, p = 0.002) and overall survival (median: 4.2 vs. 10.4 months; HR 0.22, p < 0.0001) compared with patients with normal levels. An increase of lactate dehydrogenase level during treatment was significantly associated with disease progression (p = 0.014). Multivariate Cox analysis identified LDH (HR = 0.18), C-reactive protein (HR = 0.27), number of involved organs (HR = 0.31), absolute monocyte count (HR = 0.33) and Eastern Cooperative Oncology Group performance status (HR = 0.36) as independent prognostic factors. Conclusions: Serum LDH, as is readily available in routine clinical practice, is a potential marker for response and a powerful independent factor for survival in advanced ESCC patients receiving anti-PD-1 treatment.

Sign in / Sign up

Export Citation Format

Share Document